Cara Therapeutics (Cara Therapeutics) Days Sales Outstanding : 92.89 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Days Sales Outstanding?

Cara Therapeutics's average Accounts Receivable for the three months ended in Dec. 2023 was $3.06 Mil. Cara Therapeutics's Revenue for the three months ended in Dec. 2023 was $3.00 Mil. Hence, Cara Therapeutics's Days Sales Outstanding for the three months ended in Dec. 2023 was 92.89.

The historical rank and industry rank for Cara Therapeutics's Days Sales Outstanding or its related term are showing as below:

CARA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 28.42 Med: 40.43 Max: 89.01
Current: 89.01

During the past 13 years, Cara Therapeutics's highest Days Sales Outstanding was 89.01. The lowest was 28.42. And the median was 40.43.

CARA's Days Sales Outstanding is ranked worse than
60.63% of 889 companies
in the Biotechnology industry
Industry Median: 71.03 vs CARA: 89.01

Cara Therapeutics's Days Sales Outstanding declined from Dec. 2022 (180.25) to Dec. 2023 (92.89).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Cara Therapeutics Days Sales Outstanding Historical Data

The historical data trend for Cara Therapeutics's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Days Sales Outstanding Chart

Cara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

28.42

52.44

Cara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															180.25	69.02	106.54	126.35	92.89

Competitive Comparison of Cara Therapeutics's Days Sales Outstanding

For the Biotechnology subindustry, Cara Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cara Therapeutics's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Days Sales Outstanding falls into.

Cara Therapeutics Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cara Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (3.26	+	2.765)	/	2 )	/	20.968	*	365
=	3.0125					/	20.968	*	365
=	52.44

Cara Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (3.351	+	2.765)	/	2 )	/	3.004	*	365 / 4
=	3.058					/	3.004	*	365 / 4
=	92.89

Cara Therapeutics (NAS:CARA) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Cara Therapeutics Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics (Cara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

69C:Germany 69C:Germany

Address

107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Executives

Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves	officer: Chief Medical Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion	officer: Sec'y; Chief Compliance & G.C.	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d.	officer: VP-Research & Development	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von	director	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum	director	675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard	officer: Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd	10 percent owner
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr	director
Thomas Charles Reilly	officer: Chief Financial Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd.	10 percent owner	RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027